Markus Jutzi1, Behrouz Mansouri Taleghani2, Morven Rueesch3, Lorenz Amsler4, Andreas Buser5. 1. Interregional Blood Transfusion SRC Ltd., Bern, Switzerland. 2. University Clinic of Hematology and Central Hematology Laboratory, Division of Transfusion Medicine, Bern University Hospital, Inselspital, Bern, Switzerland. 3. Blood Transfusion Service, Swiss Red Cross, Bern, Switzerland. 4. Division Safety of Medicines, Swissmedic, Bern, Switzerland. 5. Regional Blood Transfusion Service, Swiss Red Cross, Basel, and Department of Hematology, University Hospital Basel, Basel, Switzerland.
Abstract
INTRODUCTION: Bacterial contamination of platelet concentrates (PCs) has been identified as the most prevalent transfusion-associated infectious risk. To prevent PC-related septic transfusion reactions, the Intercept® pathogen inactivation procedure was introduced for all PCs in Switzerland in 2011. METHODS: Based on numbers of transfused units and mandatorily reported adverse events with high imputability, we compare the risks associated with transfusion of conventional PCs (cPCs) and pathogen-inactivated PCs (PI-PCs). RESULTS: From 2005 to 2011, a total of 158,502 cPCs have been issued in Switzerland, and 16 transfusion-transmitted bacterial infections (including 3 fatalities) were reported. This corresponds to a morbidity and mortality rate of ca. 1:9,900 and 1:52,800, respectively. From 2011 to 2016, a total of 205,574 PI-PCs have been issued, and no transfusion-transmitted bacterial infection was reported. Despite continuously increasing transfusion reaction rates per 1,000 RBC and plasma issued between 2008 and 2016, we observed reductions of 66% for life-threatening and fatal reactions and of 26% for all high-imputability transfusion reactions related to PI-PCs as compared to cPCs. No increased rates of bleeding or clinical observations of ineffectiveness of PI-PCs have been reported. After implementation of PI-PCs, the annual increase in platelet usage per 1,000 inhabitants decelerated. DISCUSSION: Swiss hemovigilance data confirm a favorable safety profile of the nationwide introduced Intercept pathogen inactivation procedure and its reliable prevention of septic transfusion reactions and fatalities due to bacterially contaminated PCs.
INTRODUCTION: Bacterial contamination of platelet concentrates (PCs) has been identified as the most prevalent transfusion-associated infectious risk. To prevent PC-related septic transfusion reactions, the Intercept® pathogen inactivation procedure was introduced for all PCs in Switzerland in 2011. METHODS: Based on numbers of transfused units and mandatorily reported adverse events with high imputability, we compare the risks associated with transfusion of conventional PCs (cPCs) and pathogen-inactivated PCs (PI-PCs). RESULTS: From 2005 to 2011, a total of 158,502 cPCs have been issued in Switzerland, and 16 transfusion-transmitted bacterial infections (including 3 fatalities) were reported. This corresponds to a morbidity and mortality rate of ca. 1:9,900 and 1:52,800, respectively. From 2011 to 2016, a total of 205,574 PI-PCs have been issued, and no transfusion-transmitted bacterial infection was reported. Despite continuously increasing transfusion reaction rates per 1,000 RBC and plasma issued between 2008 and 2016, we observed reductions of 66% for life-threatening and fatal reactions and of 26% for all high-imputability transfusion reactions related to PI-PCs as compared to cPCs. No increased rates of bleeding or clinical observations of ineffectiveness of PI-PCs have been reported. After implementation of PI-PCs, the annual increase in platelet usage per 1,000 inhabitants decelerated. DISCUSSION: Swiss hemovigilance data confirm a favorable safety profile of the nationwide introduced Intercept pathogen inactivation procedure and its reliable prevention of septic transfusion reactions and fatalities due to bacterially contaminated PCs.
Authors: J C Osselaer; J P Cazenave; M Lambermont; O Garraud; M Hidajat; L Barbolla; R Tardivel; L Defoin; C Waller; I Mendel; J P Raidot; G Kandel; R De Meuter; P Fabrigli; D Dehenau; J L Arroyo; F Padrón; H Gouezec; M Corral; M Jacquet; D Sundin; L Lin; L Corash Journal: Vox Sang Date: 2008-01-30 Impact factor: 2.144
Authors: Jeffrey McCullough; David H Vesole; Richard J Benjamin; Sherrill J Slichter; Alvaro Pineda; Edward Snyder; Edward A Stadtmauer; Ileana Lopez-Plaza; Steven Coutre; Ronald G Strauss; Lawrence T Goodnough; Joy L Fridey; Thomas Raife; Ritchard Cable; Scott Murphy; Frank Howard; Kathryn Davis; Jin-Sying Lin; Peyton Metzel; Laurence Corash; Antonis Koutsoukos; Lily Lin; Donald H Buchholz; Maureen G Conlan Journal: Blood Date: 2004-05-11 Impact factor: 22.113
Authors: Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness Journal: Transfusion Date: 2019-05-29 Impact factor: 3.157
Authors: A M Hashem; A M Hassan; A M Tolah; M A Alsaadi; Q Abunada; G A Damanhouri; S A El-Kafrawy; M Picard-Maureau; E I Azhar; S I Hindawi Journal: Transfus Med Date: 2019-11-06 Impact factor: 2.019
Authors: Burak Bahar; Wade L Schulz; Amit Gokhale; Bryan R Spencer; Eric A Gehrie; Edward L Snyder Journal: Br J Haematol Date: 2019-09-30 Impact factor: 6.998
Authors: Laura Infanti; Andreas Holbro; Jakob Passweg; Daniel Bolliger; Dimitrios A Tsakiris; Ramona Merki; Alexandra Plattner; David Tappe; Johannes Irsch; Jin-Sying Lin; Laurence Corash; Richard J Benjamin; Andreas Buser Journal: Transfusion Date: 2019-10-01 Impact factor: 3.157
Authors: Veronika Brixner; Gesine Bug; Petra Pohler; Doris Krämer; Bernd Metzner; Andreas Voss; Jochen Casper; Ulrich Ritter; Stefan Klein; Nael Alakel; Rudolf Peceny; Hans G Derigs; Frank Stegelmann; Martin Wolf; Hubert Schrezenmeier; Thomas Thiele; Erhard Seifried; Hans-Hermann Kapels; Andrea Döscher; Eduard K Petershofen; Thomas H Müller; Axel Seltsam Journal: Haematologica Date: 2021-04-01 Impact factor: 9.941